Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 25, 2015 5:49 PM ET


Company Overview of Paratek Pharmaceuticals, Inc.

Company Overview

Paratek Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry in the United States. Its lead product candidate, omadacycline, is a tetracycline-derived and broad-spectrum antibiotic developed in oral tablet and intravenous formulations for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other serious community-acquired bacterial infections. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III trials planne...

75 Kneeland Street

Boston, MA 02111

United States

18 Employees





Key Executives for Paratek Pharmaceuticals, Inc.

Chairman of the Board and Chief Executive Officer
Age: 56
Total Annual Compensation: $128.5K
President, Chief Medical Officer and Director
Age: 55
Total Annual Compensation: $488.8K
Chief Financial Officer and Secretary
Age: 42
Total Annual Compensation: $10.4K
Vice President of Research and Development
Age: 62
Total Annual Compensation: $226.0K
Compensation as of Fiscal Year 2014.

Paratek Pharmaceuticals, Inc. Key Developments

Paratek Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Paratek Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the year, the company reported loss from operations was $10,633,000 against $931,000 a year ago. Net loss was $10,633,000 against $1,211,000 a year ago. Net loss attributable to common stockholders was $10,633,000 or $0.74 per basic and diluted share against $1,413,000 or $20.93 per basic and diluted share a year ago.

Paratek Pharmaceuticals, Inc. Approves Amendments to Amended and Restated Bylaws

On April 10, 2015, the Board of Directors of Paratek Pharmaceuticals, Inc. approved amendments to Amended and Restated Bylaws, or the New Bylaws, which supersede and replace prior Amended and Restated Bylaws, effective immediately. The New Bylaws, among other things, provide that: To be timely, written notice of nominations for election to the Board of Directors and proposals to be included in proxy materials, to be properly brought before an annual meeting by a stockholder, must be received at principal executive offices not later than the close of business on the 90th day nor earlier than the close of business on the 120th day prior to the first anniversary of the preceding year’s annual meeting; provided, however, that in the event the date of the annual meeting is advanced more than 30 days prior to or delayed by more than 30 days after the anniversary of the preceding year’s annual meeting, notice by the stockholder must be received not earlier than the close of business on the 120th day prior to such annual meeting and not later than the close of business on the later of the 90th day prior to such annual meeting or the 10th day following the day on which public announcement of the date of such meeting is first made; The Court of Chancery of the State of Delaware will be the exclusive forum for any derivative action or proceeding brought on their behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against them arising pursuant to the Delaware General Corporation Law, certificate of incorporation or bylaws; or any action asserting a claim against the company that is governed by the internal affairs doctrine.

Paratek Pharmaceuticals, Inc. Announces Financial Results for the Year Ended December 31, 2014

Paratek Pharmaceuticals, Inc. announced financial results for the year ended December 31, 2014. For the year, the company reported a net loss of $19.8 million, or $7.82 per share, compared to a net loss of $11.4 million, or $185.13 per share, for the year ended December 31, 2013. Revenue in 2014 was $4.3 million, consisting of a $4.0 million milestone payment from Actavis Plc earned during the fourth quarter for the start of a Phase 3 clinical trial for sarecycline and recognition of $0.3 million in deferred revenue upon the termination of a collaborative research, development and commercialization agreement with a leading global animal health provider. Loss from operations was $17,835,000 compared to $7,540,000 a year ago.

Similar Private Companies By Industry

Company Name Region
Pharmelle LLC United States
Heritage Consumer Products, Inc. United States
Scholar Rock, Inc. United States
Chronohealth, LLC United States
Clinical Site Services Corporation United States

Recent Private Companies Transactions

July 1, 2014
Transcept Pharmaceuticals, Inc.
Private Placement
June 30, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Paratek Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at